Monographie - Clonazepam - Stabilis 4.0

Ultimo aggiornamento :
05/12/2025

Antiepilettico

Clonazepam

Iniezione

Soluzione orale

Stabilità in soluzione

Stabilità in miscela

Fattori che influenzano la stabilità

Compatibilità

metodo di iniezione

Bibliografia

pdf

Struttura chimica

Nome commerciale

Nome commerciale

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Clonazepamum	Polonia
Kriadex	Messico
Ravotril	Chile
Rivotril	Colombia, Emirati Arabi Uniti, Francia, Germania, nuova Zelanda, Paesi Bassi, Polonia, Spagna, Svizzera, Ungheria

Bibliografia

Iniezione

Bibliografia : Clonazepam

	tipo	pubblicazione
939	Rivista	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
1189	Rivista	Nation RL, Hackett LP, Dusci LJ. Uptake of clonazepam by plastic intravenous infusion bags and administration sets. Am J Hosp Pharm 1983 ; 40: 1692-1693.
1246	Rivista	Hooymans PM, Janknegt R, Lohman JJHM. Comparison of clonazepam sorption to polyvinyl chloride-coated and polyethylene-coated tubings. Pharm Weekbl [Sci] 1990 ; 12: 188-189.
1508	Rivista	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
2115	Rivista	Schneider JJ, Good Ph, Ravenscroft PJ,. Effect of tubing on loss of clonazepam administered by continuous subcutaneous infusion. J Pain Symptom Manage 2006 ; 31, 6: 563-567.
2217	Rivista	Guchelaar H.J, Hartog M.E. De stabiliteit van clonazepaminjectievloeistof. Ziekenhuisfarmacie 1997 ; 13, 1: 21-23.
3184	Laboratorio	Hyaluronidase (Hyalase®) - Summary of Product characteristics. CP Pharmaceuticals 2005
3617	Laboratorio	Hyaluronidase (Hyalase®) - Summary of Product Characteristics Wockhardt 2011
3728	Rivista	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3823	Rivista	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l’unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3976	Rivista	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4867	poster	Dazan D, Aït Taleb S, Laroyenne N, Hamam Y, Conreur L, Paoli-Lombardo R, Primas N, Lamy E, Castera-Ducros C, Curti C et al. Etude des compatibilités entre la nalbuphine et d'autres principes actifs pour optimiser leur administration en service de pédiatrie. CSH (SNPHPU) Congress sept 2024 2024
4972	Laboratorio	RIVOTRIL 1 mg/1 ml, solution à diluer injectable en ampoules - Résumé des caractéristiques du produit. CHEPLAPHARM ARZNEIMITTEL GMBH 2025

Mentions Légales